Actively Recruiting
Study to Test Relacorilant with Other Treatments for Women With Gynecological Cancers
Led by Corcept Therapeutics · Updated on 2026-07-16
270
Participants Needed
49
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of relacorilant combined with other treatments in patients with gynecological cancers in this Phase 2, open-label, global, multi-arm study. The study aims to test different treatment combinations in separate groups, including patients with ovarian and endometrial cancers, to assess how these combinations may affect disease progression and patient health. Participants in Arms A and B will receive relacorilant combined with nab-paclitaxel and bevacizumab. Relacorilant is given orally once daily under fed conditions for three days around the time of nab-paclitaxel infusion, which is administered intravenously on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is given intravenously on Days 1 and 15 in Arms A and B. Arm C participants receive relacorilant with nab-paclitaxel but without bevacizumab. Treatment continues until disease progression, unacceptable side effects, or other criteria lead to discontinuation. During the study, participants will have their cancer progression monitored through measures like progression-free survival up to 18 months. Researchers will also assess response rates, duration of response, clinical benefit, overall survival, and collect drug concentration data at specified cycle days. Safety will be monitored through adverse event reporting from the first dose until 30 days after treatment ends. The study is expected to be completed by December 2026.
CONDITIONS
Brief Title
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Research Team
C
Corcept Therapeutics
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here